Ex Vivo Microtumor Testing to Predict Chemotherapy Responses in Patients with Bladder Cancer

Guidance of adjuvant instillation in intermediate-risk non-muscle invasive bladder cancer by drug screens in patient derived organoids: a single center, open-label, phase II trial

10.1186/s12894-023-01262-1 · doi-reference

Integrative drug screening and multiomic characterization of patient-derived bladder cancer organoids reveal novel molecular correlates of gemcitabine response

10.1016/j.eururo.2024.05.026 · doi-reference

Tumor evolution and drug response in patient-derived organoid models of bladder cancer

10.1016/j.cell.2018.03.017 · doi-reference

An ex vivo tissue culture model for the assessment of individualized drug responses in prostate and bladder cancer

10.3389/fonc.2018.00400 · doi-reference

Bladder cancer organoids as a functional system to model different disease stages and therapy response

10.1038/s41467-023-37696-2 · doi-reference

Feasibility of functional precision medicine for guiding treatment of relapsed or refractory pediatric cancers

10.1038/s41591-024-02848-4 · doi-reference

Proof-of-concept study linking ex vivo sensitivity testing to neoadjuvant anthracycline-based chemotherapy response in breast cancer patients

10.1038/s41523-023-00583-6 · doi-reference

Ex vivo drug response profiling for response and outcome prediction in hematologic malignancies: the prospective non-interventional SMARTrial

10.1038/s43018-023-00645-5 · doi-reference

Implementing a functional precision medicine tumor board for acute myeloid leukemia

10.1158/2159-8290.cd-21-0410 · doi-reference

Functional precision medicine provides clinical benefit in advanced aggressive hematologic cancers and identifies exceptional responders

10.1158/2159-8290.cd-21-0538 · doi-reference

Association of molecular subtypes with pathologic response, PFS, and OS in a Phase II study of COXEN with neoadjuvant chemotherapy for muscle-invasive bladder cancer

10.1158/1078-0432.ccr-23-0602 · doi-reference

Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy

10.1016/j.eururo.2017.03.030 · doi-reference

Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy

10.1016/j.ccr.2014.01.009 · doi-reference

Correlative analysis of ATM, RB1, ERCC2, and FANCC mutations and pathologic complete response after neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: results from the SWOG S1314 trial

10.1016/j.eururo.2024.06.018 · doi-reference

Clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma

10.1001/jamaoncol.2016.1056 · doi-reference

Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer

10.1016/j.eururo.2015.07.009 · doi-reference

Inlexzo (gemcitabine intravesical system): promising data but key questions remain

10.1007/s00345-025-05955-0 · doi-reference

Intravesical gemcitabine for non-muscle invasive bladder cancer: an abridged Cochrane Review

10.4111/icu.20210265 · doi-reference

Ex vivo 3D micro-tumour testing platform for predicting clinical response to platinum-based therapy in patients with high-grade serous ovarian cancer

10.1038/s41698-025-01080-8 · doi-reference

Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome

10.1016/j.eururo.2013.08.052 · doi-reference

A SNaPshot assay for the rapid and simple detection of four common hotspot codon mutations in the PIK3CA gene

10.1186/1756-0500-2-66 · doi-reference

A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine

10.1158/1078-0432.ccr-05-1045 · doi-reference

An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma

10.1016/s0022-5347(05)64047-5 · doi-reference

Delaying radical cystectomy after neoadjuvant chemotherapy for muscle-invasive bladder cancer is associated with adverse survival outcomes

10.1016/j.euo.2018.09.004 · doi-reference

Survival of patients with muscle-invasive urothelial cancer of the bladder with residual disease at time of cystectomy: A comparative survival analysis of treatment modalities in the national cancer database

10.3233/blc-200303 · doi-reference

Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer

10.1056/nejmoa2408154 · doi-reference

Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer

10.1016/j.eururo.2011.12.010 · doi-reference

European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines

10.1016/j.eururo.2023.08.016 · doi-reference

Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial

10.1016/s1470-2045(20)30540-4 · doi-reference

Evidence-based assessment of current and emerging bladder-sparing therapies for non–muscle-invasive bladder cancer after bacillus Calmette-Guerin therapy: a systematic review and meta-analysis

10.1016/j.euo.2020.02.006 · doi-reference

BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG

10.1038/nrurol.2017.16 · doi-reference

LBA104 First safety and efficacy results of the TAR-210 erdafitinib (erda) intravesical delivery system in patients (pts) with non–muscle-invasive bladder cancer (NMIBC) with select FGFR alterations (alt)

10.1016/j.annonc.2023.10.110 · doi-reference

Intravesical therapy for the treatment of nonmuscle invasive bladder cancer: a systematic review and meta-analysis

10.1016/j.juro.2016.12.090 · doi-reference

European Association of Urology guidelines on non–muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)

10.1016/j.eururo.2021.08.010 · doi-reference